VBValentina Bartolomeo

Valentina Bartolomeo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Valentina Bartolomeo has a total of 211 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

    by Arsela Prelaj, Vanja Miskovic, Matteo Sacco, Alberto Ferrarin, Cristina Maria Licciardello, Leonardo Provenzano, Margherita Favali, Ludovica Lerma, Aleksandra Zec, Andrea Spagnoletti, et al.

    Despite a decade in, immunotherapy (IO) treatment selection in non-small cell lung cancer (NSCLC) remains largely guided by subgroup analyses and imperfect programmed death ligand 1 (PD-L1) and clinical scores. To our knowledge, I 3 LUNG ( NCT05537922 ) is currently the largest international, real-world, multimodal, artificial intelligence (AI)-based study, enrolling 2,396 patients. We integrated real-world clinical and blood (CB) data, computed tomography (CT) images, digital pathology (DP), and genomics into machine learning early fusion (MLEF) and deep learning intermediate fusion (DLIF) models. Machine learning (ML) and deep learning (DL) CB-only models achieved consistent performance across outcomes with area under the curve (AUC) up to 0.77 in the test (TEST) set. Performance drop in external validation (EXVAL) likely reflects population differences (AUC range: 0.55–0.72). AI models significantly surpassed PD-L1, Eastern Cooperative Oncology Group performance status (ECOG PS), neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and Lung Immune Prognostic Index (LIPI) score in the independent TEST set. The clinical usability study showed that lung expert and nonexpert physicians improved their prediction with the explainable AI (XAI) ML CB-only based tool. Although multimodal integration with MLEF (CB+CT+DP) was associated with higher performance, its incremental benefit remains uncertain, not translated in TEST and EXVAL. The I 3 LUNG project is a pioneering framework showing the clinical usefulness of AI tools. A prospective validation of the decision support system (both CB and multimodal) is currently undergoing in more than 2,000 patients.


  • Open Access

    Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment

    by Valentina Bartolomeo, Mandy Jongbloed, Jarno W.J. Huijs, Andrea Riccardo Filippi, Ben E.E.M. van Den Borne, Cordula Pitz, Hester Gietema, Juliette Degens, Magdolen Youssef-El Soud, Michelle Steens, et al.

  • Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study

    by Francesca Rita Ogliari, Mandy Jongbloed, Rianne D. W. Vaes, Ruud M. A. Houben, Valentina Bartolomeo, Ben E. E. M. van Den Borne, Juliette Degens, Jarno W. J. Huijs, Cordula Pitz, Michelle Steens, et al.

    Purpose Current guidelines recommend adding local radical therapy (LRT) to systemic treatment in synchronous oligometastatic non-small-cell lung cancer (sOM-NSCLC), but survival data on immunotherapy-based regimens are limited. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are prognostic in NSCLC, with higher values linked to worse outcomes. This study examines their association with survival in sOM-NSCLC patients treated with immunotherapy. Methods We conducted a multicenter retrospective study including all consecutive patients with [18F]FDG-PET and brain imaging-staged sOM-NSCLC, between 2015 and 2022, who received first-line (chemo)-immunotherapy and had baseline PET-scan available for review. Subgroups were analyzed based on median MTV and TLG values (high vs. low: H-MTV vs. L-MTV, H-TLG vs. L-TLG). Study endpoints were progression-free survival (PFS) and overall survival (OS), according to MTV and TLG distribution (high vs. low), in the overall population (primary endpoint) and in relation to LRT and systemic treatment type (secondary endpoints). Results 105 patients were included, 50% were male and 73% had non-squamous histology, median age was 64.9 years. Median PFS was significantly longer for L-MTV vs. H-MTV (14.73 months (95%CI, 7.06–22.40) vs. 7.63 months (95%CI, 5.73–9.52), p = 0.028), but also LRT was associated with PFS (19.04 months (95%CI, 8.47–29.60) versus 7.46 months (95%CI, 5.25–9.67), p = 0.045), while neither MTV nor TLG had impact on OS. In multivariate analysis, only PD-L1 < 50% and soft tissue metastases remained significantly associated with shorter PFS. Conclusions Baseline MTV is preliminarily associated with PFS in sOM-NSCLC patients treated with immunotherapy, but results are exploratory and need prospective validation in larger cohorts.


  • Open Access

    Integrating radiomics and real-world data to predict immune checkpoint inhibitor efficacy in advanced non-small-cell lung cancer

    by L. Provenzano, M. Favali, L. Mazzeo, A. Spagnoletti, M. Ruggirello, G. Calareso, F.G. Greco, R. Vigorito, A. Quarta, F. Calimeri, et al.


  • Top Cited Papers
    Open Access

    Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: An ESTRO clinical practice guideline

    by Dirk De Ruysscher, Els Wauters, Verena Jendrossek, Andrea Riccardo Filippi, Marie-Pierre Revel, Corinne Faivre-Finn, Jarushka Naidoo, Sara Ramella, Matthias Guckenberger, Umberto Ricardi, et al.


  • Open Access

    Cachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable?

    by Valentina Bartolomeo, Mandy Jongbloed, Wouter R. P. H. van de Worp, Ramon Langen, Juliette Degens, Lizza E. L. Hendriks, Dirk K. M. de Ruysscher

    Among patients with advanced NSCLC, there is a group of patients with synchronous oligometastatic disease (sOMD), defined as a limited number of metastases detected at the time of diagnosis. As cachexia and sarcopenia are linked to poor survival, incorporating this information could assist clinicians in determining whether a radical treatment should be administered. In a retrospective multicenter study, including all patients with adequately staged (FDG-PET, brain imaging) sOMD according to the EORTC definition, we aimed to assess the relationship between cachexia and/or sarcopenia and survival. Of the 439 patients that were identified between 2015 and 2021, 234 met the criteria for inclusion and were included. The median age of the cohort was 67, 52.6% were male, and the median number of metastasis was 1. Forty-six (19.7%) patients had cachexia, thirty-four (14.5%) had sarcopenia and twenty-one (9.0%) had both. With a median follow-up of 49.7 months, median PFS and OS were 8.6 and 17.3 months, respectively. Moreover, a trend toward longer PFS was found in patients without cachexia and sarcopenia compared to those with cachexia and/or sarcopenia. In multivariate analysis, cachexia and sarcopenia were not associated with an inferior survival, irrespective of receiving radical treatment. High CRP was associated with inferior survival and could be a prognostic factor, helping the decision of clinicians in selecting patients who may benefit from the addition of LRT. However, despite the homogeneous definition of oligometastatic disease and the adequate staging, our subgroups were small. Therefore, further studies are needed to better understand our hypothesis and generating findings.